CVRx posted a strong third quarter with a 10% year-over-year revenue increase, driven by strategic sales force enhancements and expanded commercial reach.

• Revenue reached $14.7 million, with U.S. sales growing to $13.5 million, reflecting robust heart failure business expansion.
• The company onboarded 10 new active implanting centers, bringing the total to 250, alongside a growth in sales territories to 50.
• Momentum in adoption of Barostim therapy is underscored by more than 20% of centers performing three or more implants in Q3.
• Advancements in reimbursement, including a proposed Category I CPT code effective January 2026, are expected to improve physician payment structures.
• A strong presence at the Heart Failure Society of America meeting highlighted growing interest and clinical validation of Barostim therapy.